The stock trades at $15.22. The company is guiding toward its first profitable year. Two FDA approvals landed in the past six weeks. On paper, those three facts should not coexist with a share price that has fallen nearly half in the past twelve months and sits at the lowest valuation multiple in its own decade of history. Something broke the usual logic, and the filing record shows exactly what.
In one breath
Ultragenyx has grown revenue every year since 2021, and its losses are shrinking fast. The stock’s price-to-sales multiple, a measure of what investors pay per dollar of revenue, has collapsed to 2.2 times, against a decade median of 10.1 times, putting it at the first percentile of its own history, according to our data. That gap exists because a single Phase 3 trial failed in September 2026, erasing the market’s confidence in the pipeline that was supposed to justify a premium price. The open question is whether two fresh FDA approvals and a narrowing loss can rebuild that confidence before the cash runway runs short.
How a company gets to the first percentile of its own history
Ultragenyx was built on a specific bet: that ultra-rare genetic diseases, the kind affecting a few thousand patients worldwide, could support commercial-scale drug prices because no alternatives existed. For most of its public life, investors paid a steep premium for that thesis. The decade-median price-to-sales multiple of 10.1 times, our data show, reflects years when the market believed the pipeline would keep delivering. Crysvita, the company’s lead product for a rare bone disease, validated the model. The 2025 annual report shows Crysvita alone generated the large majority of the year’s total revenue, meaning one drug accounts for roughly seven of every ten dollars the company earns.
That concentration was always a known risk. What the market did not fully price was the clinical risk sitting beside it. In early September 2026, the Phase 3 Aspire study for GTX-102, an experimental therapy for Angelman syndrome, failed to meet its primary or any key secondary endpoint. Angelman syndrome affects children’s ability to speak, walk, and sleep; the patient community had waited years for a treatment. The failure was not just a commercial disappointment. It was a signal that the pipeline’s most watched bet had not come through. Analysts at RBC Capital Markets, Bank of America, Baird, and Evercore ISI responded with price-target cuts of more than half at several firms. The stock followed.
What the filings actually show
Here is the tension the filings create. While the market was repricing the pipeline downward, the income statement was moving in the opposite direction. The 10-Q for the quarter ended June 30, 2026 shows a net loss that sounds large in isolation, but the trend matters: the net margin has improved from deeply negative in 2022 to roughly negative 85% in 2025, per our data. The company is losing less of each revenue dollar every year, steadily, not in fits.
The cash position is where the story gets complicated. The 10-Q for the quarter ended June 30, 2026 shows Ultragenyx held $436 million in cash and equivalents as of that date. Early in 2026, the company burned through cash quickly due to restructuring charges tied to the February 2026 workforce reduction of roughly one in ten employees. By the second quarter, the burn rate had fallen by more than half. At that lower rate, the runway extends to roughly four to five quarters. That is not comfortable, but it is not a crisis either, assuming the commercial launches now underway begin contributing revenue.
Two approvals the price does not seem to know about
Six weeks before this article, on September 17, 2026, the FDA granted full approval to FAYUVI, a gene therapy for Sanfilippo syndrome Type A, a devastating childhood neurological disease with no prior treatment. The FDA’s approval announcement marked it as the first gene therapy for the condition. The wholesale price is set at $3.95 million per patient before rebates, consistent with how single-administration gene therapies are priced across the industry. A month earlier, GENGLYCOS received accelerated approval for a rare metabolic disorder called Glycogen Storage Disease Type Ia.
Both approvals arrived after the GTX-102 failure. Both are excluded from the company’s current full-year revenue guidance, which management reaffirmed on the Q2 2026 earnings call. That means any revenue these two therapies generate in the second half of 2026 sits entirely outside the guided range. Gene therapies for ultra-rare diseases typically launch slowly, because the eligible patient population is tiny and treatment centers need qualification. But the commercial infrastructure is now in place, and the math of a nearly four-million-dollar price tag means even a handful of patients treated changes the revenue picture meaningfully.
FAYUVI itself has a complicated history worth noting. The FDA initially rejected it in July 2025 over manufacturing concerns. Ultragenyx resolved those issues and resubmitted, earning full approval roughly fourteen months later. That sequence, rejection then resolution, is not unusual in gene therapy, but it cost the company time and contributed to the stock’s decline through 2025 and into 2026.
Reading the numbers
- Price-to-sales multiple: 2.2 times, against a decade median of 10.1 times (first percentile of own history). A price-to-sales multiple is simply the market’s total value for the company divided by its annual revenue. Think of it as the price tag per dollar of sales. At 10.1 times, investors were historically paying about ten dollars for every dollar Ultragenyx earned in revenue. At 2.2 times today, they are paying about two dollars. A household analogy: if a bakery that normally sells for ten times its annual sales suddenly sold for two times, a buyer would want to know whether the recipes stopped working or the price just overshot.
- Net loss per share: $5.83 in fiscal 2025, down from $10.12 in fiscal 2022. This is what the company loses, divided across all shares, in a year. The improvement over three years, per our data and the 2025 10-K, means the loss per share has nearly halved. That does not mean the company is profitable, but it means each year’s loss consumes less of the cash cushion than the year before.
- R&D expense: consuming roughly 78 cents of every revenue dollar in Q2 2026. Research and development spending is what the company pays to run clinical trials and develop new drugs, per the Q2 2026 10-Q. That ratio is expected to fall: management guided for combined R&D and overhead expenses to drop meaningfully in 2027 versus 2025, as multiple Phase 3 studies complete. A family spending nearly four of every five dollars earned on education costs would expect that number to fall once the tuition bills stop arriving.
- Cash runway: approximately 4 to 5 quarters at Q2 2026 burn rate. With $436 million in cash and a burn rate that fell sharply from the first quarter to the second, the company has enough to operate into late 2027 without new financing, assuming the burn rate holds. The company’s own path-to-profitability guidance targets 2027, which means the runway and the target are roughly aligned. Whether they meet in time is the question the data cannot yet answer.
Where the math and the mood diverge
The math, meaning what the filed numbers show, describes a company that has roughly doubled revenue since 2021, narrowed its losses every year, and now holds two new commercial products the market has not yet priced. The mood, meaning what investors are currently paying, reflects the September clinical failure and a decade’s worth of premium valuation being unwound in twelve months. A price-to-sales multiple at the first percentile of its own history is not a moderate discount. It is the market saying the old story is over and demanding proof of a new one.
The proof, if it comes, will arrive in the form of FAYUVI and GENGLYCOS patient numbers, an expense line that actually falls as guided, and a cash balance that holds above zero long enough for the profitability target to materialize. The data as filed show the pieces are present. Whether they assemble on schedule is a question the filings cannot answer yet, and neither can we.
Sources
- 10-Q for quarter ended June 30, 2026 (SEC EDGAR)
- 10-K for fiscal year ended December 31, 2025 (SEC EDGAR)
- February 2026 restructuring filing (SEC EDGAR)
- Q2 2026 earnings call transcript (Seeking Alpha)
- FDA approval announcement for FAYUVI (FDA.gov)
- FAYUVI approval and analyst downgrades context (DelveInsight)
- FAYUVI approval coverage (Fierce Pharma)
